AGENDA DAY 1

 

 

Day One 10th Oct Human, Vet, Immune

Panel discussion
09:00

Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?

Opening plenary discussion: Creating a new strategy: How does the current global outbreak response system need to change?
  • Efforts to develop an international fund to develop vaccines that are of low commercial interest but potentially epidemic-proof to the next emerging disease
  • Understanding the legal and regulatory framework for licensure of medical countermeasures during public health emergencies
  • How do we know which vaccines to stockpile? Initial efforts in MERS-CoV, Lassa and Nipah viruses
  • How should pharma and industry respond to developing low income vaccines?
  • What’s the global capacity and how fast can we develop a sustainable supply?
Francesca Ceddia
10:00

Maternal immunisation: Where do we stand and how do we use vaccines, antivirals and antibodies – what’s the strategy?

  • Are we vaccinating the mums to protect the babies or to protect both
  • What are the challenges and unresolved questions around maternal immunization implementation
  • What are the vaccines in development and available today?
10:30

Break the ice with your peers and exchange business cards in the conference room

Allowing conference delegates to meet each other for a short space of time and exchange business cards. A unique feature guaranteeing heightened networking for all participants
10:40

Morning Networking Break

THERAPEUTIC VACCINES TRACK WITH IMMUNE PROFILING WORLD CONGRESS

RESPIRATORY VACCINES TRACK

ONE HEALTH WORKSHOP WITH WORLD VETERINARY VACCINES CONGRESS

Therapeutic Vaccines Track With Immune Profiling
11:40

Chair’s opening remarks

Dr Emmett Schmidt, Exec Director, Clinical Research, Merck Research Laboratories - Oncology

THERAPEUTIC & IMMUNOTHERAPY VACCINES

INFLUENZA VACCINES

DISCOVERY AND DRIVERS FOR EMERGING DISEASES

Therapeutic Vaccines Track With Immune Profiling
11:45

Why haven't Alzheimer's vaccines succeeded yet?

 
  • Abeta and tau still valid AD targets
  • Past AD vaccines were very poorly immunogenic, explaining lack of efficacy
  • Structured AD vaccine design ensures maximal immune recognition
  • Good adjuvants are essential for effective AD vaccines
ONE HEALTH with Veterinary Vaccines
12:45

Virus discovery – new kids on the block with pandemic potential

 
  • Comparing diseases side by side to “human diseases”
  • The importance of pathogen identification with unknown host transfer
13:15

Networking Lunch & Poster Session

Therapeutic Vaccines Track With Immune Profiling
14:45

A pan-HLA predictor of antigen processing and presentation to the cell surface improves the identification of clinically relevant neoantigens Bullet point summary:

  •     Current neoantigen discovery algorithms do not predict processing and presentation to the cell surface very well. 
  •     We outline a high-performing machine learning approach, trained on mass-spectrometry data, that predicts naturally processed and presented antigens.
  •     We illustrate its application to significantly improve identification of neoantigen targets for personalized cancer immunotherapy 
ONE HEALTH with Veterinary Vaccines
14:45

Innovative mRNA vaccines – from proof of concept to product development, Rabies as an example

 
  • How can this global cooperative scientific reduces the risk of viral outbreaks over the next decade?
  • Challenges in doing so and hurdles needing to be overcome
  • Visionary thoughts for the future
Susanne Rauch, Senior Scientist, CureVac Gmbh
ONE HEALTH with Veterinary Vaccines
15:15

Use of vaccination in animals for total epizootic disease eradication and anti-microbial resistance control

 
  • Using vaccination as an effective mean to treat bacterial animal infections at the source
  • Development of vaccines for decreasing use of antibiotics in terrestrial and aquatic animals
  • Using vaccination as a tool for total epizootic disease eradication (Dog Rabies, FMD and PPR)
  • Potential within the veterinary vaccine industry and challenges needing to be overcome
ONE HEALTH with Veterinary Vaccines
15:45

Nanovaccines; A new platform technology for immunization against avian infections that impact human health

  • Utilizing avian influenza virus (AIV) proteins encapsulated within polyanhydride nanoparticles to develop a protective vaccine against outbreaks of high pathogenic and low pathogenic avian influenza
16:15

Networking Break

RSV VACCINES

ONE HEALTH with Veterinary Vaccines
16:45

New insight and the challenges associated with the prevention and control of Rift Valley fever

 
  • New research and new data updates
  • The significant role of early detection, notification and information sharing during transboundary disease outbreak
  • Discussing the need to employ a “One Health” approach and update on recent efforts to control the recent outbreak of RVF in West Africa using the One Health approach
  • Reassessing the current vaccination strategy for RVF
ONE HEALTH with Veterinary Vaccines
17:15

Development of proprietary polysaccharide vaccine adjuvants that meet the needs of humans and animals when concerning Influenza, West Nile and other re-emerged viruses

 
  • Novel adjuvant combinations for veterinary and human vaccines
  • Production of vaccines in line with One Health considerations
  • Challenges faced, overcome and needing to be overcome for accelerated commercialisation and market access
17:45

Chair closing remarks of day one followed by Drinks Reception

last published: 08/Oct/17 16:35 GMT